NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03728504,Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema,https://clinicaltrials.gov/study/NCT03728504,,COMPLETED,Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.,YES,Chronic Hand Dermatitis,DRUG: ASN002|DRUG: Placebo Oral Tablet,"Percent Change From Baseline in Modified Total Lesion Symptom Score (mTLSS), Percent change from baseline in hand mTLSS at Week 16. The mTLSS is an assessment of the severity of each of the following: erythema, scaling, lichenification/hyperkeratosis, vesicles, edema, fissures, and pruritus/pain. Each of these are rated using a 4-point severity scale. The ratings are added to create a total mTLSS calculated as the sum of assigned individual scores with a maximum value of 21 (most severe disease) and a minimum of 0 (no disease), 16 weeks","Change From Baseline in Hand Physician Global Assessment (PGA), Proportion of participants with a response of Physicians Global Assessment achieving clear (0) or almost clear (1), 16 weeks|Change From Baseline in Hand Patient Global Assessment (PaGA), Reduction of PaGA compared to baseline where marked improvement was noted with at least 75% clear, 16 weeks",,Asana BioSciences,,ALL,"ADULT, OLDER_ADULT",PHASE2,97,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ASN002AD-202,2019-01-03,2020-04-29,2020-04-29,2018-11-02,2023-04-13,2023-05-09,"Pinnacle Research Group, LLC, Anniston, Alabama, 36207, United States|Dermatology Research Associates, Los Angeles, California, 90045, United States|Sweet Hope Research Specialty, Inc, Hialeah, Florida, 33016, United States|RM Medical Research, Inc., Miami, Florida, 33174, United States|Advanced Clinical Research, Boise, Idaho, 83713, United States|Dawes Fretzin Clinical Research Group, Indianapolis, Indiana, 46256, United States|Dermatology Specialists Research, Louisville, Kentucky, 40241, United States|DelRicht Research, New Orleans, Louisiana, 70115, United States|Maryland Laser Skin and Vein, Hunt Valley, Maryland, 21030, United States|BTC Network, Fort Gratiot, Michigan, 48059, United States|Minnesota Clinical Research Center, Fridley, Minnesota, 55432, United States|ActivMed Practices and Research, Inc., Portsmouth, New Hampshire, 03801, United States|Dermatologists of Greater Colombus, Bexley, Ohio, 43209, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, 73112, United States|Progressive Clinical Research, San Antonio, Texas, 78213, United States|Virginia Clinical Research, Inc., Norfolk, Virginia, 23502, United States|Dermatology Specialists of Spokane, Spokane, Washington, 99202, United States|SimcoDerm Medical and Surgical Dermatology Centre, Barrie, Ontario, 73112, Canada|Wei Jing Loo Medicine Professional Corp., London, Ontario, N6H5L5, Canada|Lynderm Research Inc., Markham, Ontario, L3P1X2, Canada|G. Daniel Schachter Medicine Professional, Toronto, Ontario, M4W2N2, Canada|Innovaderm Research, Inc., Montreal, H2K4L5, Canada|Centre de Recherche Dermatologique du Quebec metropolitain, Quebec, G1V4X7, Canada","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/04/NCT03728504/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/04/NCT03728504/SAP_001.pdf"
